ProPhase Labs, Inc. (NASDAQ:PRPH) Short Interest Update

ProPhase Labs, Inc. (NASDAQ:PRPH) was the target of a large decrease in short interest in the month of January. As of January 31st, there was short interest totalling 84,900 shares, a decrease of 27.1% from the January 15th total of 116,400 shares. Based on an average daily trading volume, of 621,700 shares, the short-interest ratio is currently 0.1 days.

Hedge Funds Weigh In On ProPhase Labs

A number of hedge funds have recently made changes to their positions in PRPH. Warberg Asset Management LLC acquired a new stake in ProPhase Labs during the 4th quarter worth approximately $77,000. Renaissance Technologies LLC lifted its holdings in ProPhase Labs by 33.2% during the 4th quarter. Renaissance Technologies LLC now owns 286,485 shares of the company’s stock worth $217,000 after buying an additional 71,375 shares in the last quarter. Perritt Capital Management Inc lifted its holdings in ProPhase Labs by 129.1% during the 4th quarter. Perritt Capital Management Inc now owns 190,000 shares of the company’s stock worth $144,000 after buying an additional 107,068 shares in the last quarter. Geode Capital Management LLC lifted its holdings in ProPhase Labs by 26.6% during the 4th quarter. Geode Capital Management LLC now owns 203,528 shares of the company’s stock worth $154,000 after buying an additional 42,793 shares in the last quarter. Finally, HighTower Advisors LLC lifted its holdings in ProPhase Labs by 32.2% during the 4th quarter. HighTower Advisors LLC now owns 236,781 shares of the company’s stock worth $179,000 after buying an additional 57,736 shares in the last quarter. Hedge funds and other institutional investors own 9.45% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on shares of ProPhase Labs in a research note on Sunday, February 9th. They issued a “sell” rating for the company.

ProPhase Labs Trading Down 0.9 %

Shares of NASDAQ:PRPH traded down $0.00 during mid-day trading on Friday, reaching $0.34. 5,008,822 shares of the company were exchanged, compared to its average volume of 6,065,213. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.47 and a quick ratio of 1.33. The firm has a market cap of $8.04 million, a price-to-earnings ratio of -0.27 and a beta of -0.37. The firm’s 50-day simple moving average is $0.57 and its 200 day simple moving average is $1.58. ProPhase Labs has a 1 year low of $0.22 and a 1 year high of $7.48.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.